US FDA explains approach to medical device post-market “emerging signals”

By Stewart Eisenhart, Emergo Group

The US Food and Drug Administration has published final guidance explaining how and when the agency notifies the public of information such as adverse events involving medical devices legally marketed in the country.

Get the full story here at the Emergo Group’s blog.

The opinions expressed in this blog post are the author’s only and do not necessarily reflect those of MassDevice.com or its employees.

The post US FDA explains approach to medical device post-market “emerging signals” appeared first on MassDevice.

from MassDevice http://ift.tt/2gRHyWS